Replimune Group (NASDAQ:REPL) Receives Neutral Rating from Piper Sandler

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "neutral" rating reissued by research analysts at Piper Sandler in a research report issued to clients and investors on Tuesday, MarketBeat reports. They currently have a $3.00 target price on the stock. Piper Sandler's price target indicates a potential downside of 1.74% from the company's previous close.

REPL has been the subject of a number of other reports. Wedbush restated a "neutral" rating and set a $4.00 price objective (down from $19.00) on shares of Replimune Group in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Replimune Group in a research report on Thursday, July 3rd. JPMorgan Chase & Co. raised their price objective on Replimune Group from $16.00 to $19.00 and gave the company an "overweight" rating in a research report on Wednesday, July 16th. Finally, Cantor Fitzgerald initiated coverage on Replimune Group in a research note on Friday, June 20th. They issued an "overweight" rating on the stock. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $14.43.

Replimune Group Stock Performance

Shares of REPL stock traded down $9.28 during trading hours on Tuesday, hitting $3.05. The company's stock had a trading volume of 54,749,173 shares, compared to its average volume of 1,179,665. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average of $9.62 and a 200 day moving average of $10.46. Replimune Group has a 12-month low of $2.69 and a 12-month high of $17.00. The stock has a market cap of $235.35 million, a PE ratio of -0.99 and a beta of 0.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the firm posted ($0.25) EPS. On average, sell-side analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity

In other Replimune Group news, CEO Sushil Patel sold 25,105 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the completion of the transaction, the chief executive officer owned 343,576 shares of the company's stock, valued at approximately $2,769,222.56. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $30,179.45. Following the completion of the transaction, the insider directly owned 128,296 shares of the company's stock, valued at $1,032,782.80. The trade was a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock valued at $603,655 over the last quarter. Insiders own 8.80% of the company's stock.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Replimune Group by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 508,398 shares of the company's stock valued at $6,157,000 after purchasing an additional 23,601 shares during the last quarter. Swiss National Bank increased its position in shares of Replimune Group by 57.4% in the 4th quarter. Swiss National Bank now owns 103,700 shares of the company's stock valued at $1,256,000 after purchasing an additional 37,800 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Replimune Group in the 4th quarter valued at approximately $189,000. American Century Companies Inc. increased its position in shares of Replimune Group by 32.2% in the 4th quarter. American Century Companies Inc. now owns 111,850 shares of the company's stock valued at $1,355,000 after purchasing an additional 27,259 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Replimune Group in the 4th quarter valued at approximately $148,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.